Functional renin receptors in renal mesangial cells

Current Hypertension Reports

Volumn 9, Issue 2, 2007, Pages 133-139

  Huang, Yufeng ^b   Border, Wayne A ^b   Noble, Nancy A ^a  

^a Fibrosis Research Laboratory   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PRORENIN; RENIN;

CARDIOVASCULAR DISEASE; CATALYSIS; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANIMALS; HUMANS; KIDNEY DISEASES; MESANGIAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 34249080813     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0024-4     Document Type: Review

References (57)

1. Neuringer JR, Brenner BM: Hemodynamic theory of progressive renal disease: A 10 year update in brief review. Am J Kidney Dis 1993, 22:98-104.
2. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992, 140:95-107.
3. Kagami S, Border WA, Miller DE, et al.: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437.
4. Kagami S, Kuhara I, Okada K, et al.: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997, 51:664671.
5. Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998, 54:1570-1580.
6. Morgan T, Anderson A, Bertram D, et al.: Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 2004, 5:64-71.
7. Forclaz A, Maillard M, Nussberger J, et al.: Angiotensin II receptor blockade: is there truly benefit of adding an ACE inhibitor? Hypertension 2003, 41:31-36.
8. Doulton TW: ACE inhibitor-angiotensin receptor blocker combinations: a clinician's perspective. Mini Rev Med Chem 2006, 6:491-497.
9. Azizi M, Menard J: Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004, 109:2492-2499.
10. Wolf G: Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006, 70:1914-1919.
11. Luetscher JA, Kraemer FB, Wilson DM, et al.: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985, 312:1412-1417.
12. Nguyen G, Delarue F, Berrou J, et al.: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996, 50:1897-1903.
13. Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
14. Griendling KK, Murphy TJ, Alexander RW: Molecular biology of the renin-angiotensin system. Circulation 1993, 87:1816-1828.
15. Danser AH, van Kats JP, Admiraal PJ, et al.: Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994, 24:37-48.
16. Katz SA, Opsahl JA, Lunzer MM, et al.: Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Hypertension 1997, 30:259-266.
17. Muller DN, Fischli W, Clozel JP, et al.: Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res 1998, 82:13-20.
18. Schmitz C, Gotthardt M, Hinderlich S, et al.: Normal blood pressure and plasma renin activity in mice lacking the renin-binding protein, a cellular renin inhibitor. J Biol Chem 2000, 275:15357-15362.
19. Saris JJ, Derkx FH, De Bruin RJ, et al.: High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol Heart Circ Physiol 2001, 280:H1706-1715.
20. Saris JJ, van den Eijnden MM, Lamers JM, et al.: Prorenin-induced myocyte proliferation: no role for intracellular angiotensin II. Hypertension 2002, 39:573-577.
21. Peters J, Farrenkopf R, Clausmeyer S, et al.: Functional significance of prorenin internalization in the rat heart. Circ Res 2002, 90:1135-1141.
22. Sealey JE, Catanzaro DF, Lavin TN, et aL: Specific prorenin/renin binding (ProBP)-identification and characterization of a novel membrane site. Am J Hypertens 1996, 9:491-502.
23. Ichihara A, Hayashi M, Kaneshiro Y, et al.: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004, 114:1128-1135.
24. Niimura F, Labosky PA, Kakuchi J, et al.: Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995, 96:2947-2954.
25. Tsuchida S, Matsusaka T, Chen X, et al.: Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998, 101:755-760.
26. Esther CR Jr, Howard TE, Marino EM, et al.: Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996, 74:953-965.
27. Ray PE, McCune B, Gomez RA, et al.: Expression of transforming growth factor 3 in hypertrophic juxtaglomerular apparatus. N Engl J Med 1994, 330:68-69.
28. Ray PE, McCune BK, Gomez RA, et al.: Renal vascular induction of TGF-2 and renin by potassium depletion. Kidney Int 1993, 44:1006-1013.
29. Border WA, Noble NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998, 31:181-188.
30. Huang Y, Wongamorntham S, Kasting J, et al.: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006, 69:105-113.
31. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74:49-139.
32. Cobb MH, Goldsmith EJ: How MAP kinases are regulated. J Biol Chem 1995, 270:14843-14846.
33. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52:11-34.
34. Touyz RM, El Mabrouk M, He G, et al.: Mitogen-activated protein/ extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res 1999, 84:505-515.
35. Naito T, Masaki T, Nikolic-Paterson DJ, et al.: Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 2004, 286:F278-287.
36. Gorin Y, Ricono JM, Wagner B, et al.: Angiotensin II-induced ERK1/ ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J 2004, 381:231-239.
37. Huang Y, Noble NA, Border WA: Renin-stimulated TGFβ expression in mesangial cells is MAPK-mediated [abstract]. J Am Soc Nephrol 2006, 17:SA-P0273.
38. Kaneshiro Y, Ichihara A, Takemitsu T, et al.: Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006, 70:641-646.
39. Burckle CA, Jan Danser AH, Mullet DN, et al.: Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006, 47:552-556.
40. Morris BJ: Molecular biology of renin. Part 1: gene and protein structure, synthesis and processing. J Hypertens 1992, 10:209-214.
41. Hsueh WA, Baxter JD: Human prorenin. Hypertension 1991, 17:469-477.
42. Danser AH, Deinum J: Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005, 46:1069-1076.
43. van den Eijnden MM, Saris JJ, de Bruin RJ, et al.: Prorenin accumulation and activation in human endothelial cells: importance of mannose 6-phosphate receptors. Arterioscler Thromb Vasc Biol 2001, 21:911-916.
44. Saris JJ, Derkx FH, Lamers JM, et al.: Cardiomyocytes bind and activate native human prorenin: role of soluble mannose 6-phosphate receptors. Hypertension 2001, 37:710-715.
45. Jan Danser AH, Saris JJ: Prorenin uptake in the heart: a prerequisite for local angiotensin generation? J Mol Cell Cardiol 2002, 34:1463-1472.
46. Lenz T, Sealey JE, Lappe RW, et al.: Infusion of recombinant human prorenin into rhesus monkeys. Effects on hemodynamics, renin-angiotensin-aldosterone axis and plasma testosterone. Am J Hypertens 1990, 3:257-261.
47. Veniant M, Menard J, Bruneval P, et al.: Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996, 98:1996-1970.
48. Prescott C, Silversides DW, Reudelhuber TL: Tissue activity of circulating prorenin. Am J Hypertens 2002, 15:280-285.
49. Ichihara A, Kaneshiro Y, Takemitsu T, et al.: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006, 47:894-900.
50. Ichihara A, Kaneshiro Y, Takemitsu T, et al.: Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 2006, 17:2495-2503.
51. Sarofuka S, Ichihara A, Nagai N, et al.: Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci 2006, 47:2686-2692.
52. Ichihara A, Suzuki F, Nakagawa T, et al.: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006, 17:1950-1961.
53. Saris JJ, 't Hoen PA, Garrelds IM, et al.: Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006, 48:564-571.
54. Burridge K, Wennerberg K: Rho and Rac take center stage. Cell 2004, 116:167-179.
55. Fisher ND, Hollenberg NK: Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005, 16:592-599.
56. Wood JM, Maibaum J, Rahuel J, et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698-705.
57. Azizi M, Webb R, Nussberger J, et al.: Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006, 24:243-256.